Serum insulin
Serum insulin has been studied in 1 paper since 2025: 1 observational study in people; 1 in the past year. The newest paper, Nov 19, 2025: “Nonlinear association between glycemic markers and incident cardio‑renal‑metabolic multimorbidity: two decades of follow‑up in the Tehran Lipid and Glucose Study”.
1 paper studies it1 findingUpdated
See all 1 papers on serum insulin
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Hazard ratios (HRs) of incident CRMM associated with each 1-standard deviation (SD) increase in FPG, 2hPG, insulin (natural log), and HOMA-IR (natural log) were 1.48 (95 % CI: 1.34-1.64)”
- 1 lab in 1 country
- Humans1
What did studies of serum insulin find?
1Studies of serum insulin measured one outcome, cardio-renal-metabolic multimorbidity.
Cardio-renal-metabolic multimorbidity
no changein humans1HR 1.1
1 study
Cardio-renal-metabolic multimorbidity
no changein humans1HR 1.1
Serum insulin was not clearly linked with cardio-renal-metabolic multimorbidity in humans (per 1-standard deviation increase in natural log) (HR 1.10 (95% CI 0.91-1.32) per 1-SD increase in natural log).
“Hazard ratios (HRs) of incident CRMM associated with each 1-standard deviation (SD) increase in FPG, 2hPG, insulin (natural log), and HOMA-IR (natural log) were 1.48 (95 % CI: 1.34-1.64)”
Humansper 1-standard deviation increase in natural logmedian follow-up of 15.3 years
American journal of preventive cardiology